**The primary driver of trader sentiment for broader marijuana rescheduling remains the expedited DEA administrative hearing that began June 29, 2026, and was scheduled to conclude no later than July 15.** This proceeding follows President Trump's December 2025 executive order directing swift completion of the rulemaking to move cannabis from Schedule I to Schedule III under the Controlled Substances Act, building on the 2024 notice of proposed rulemaking. In April 2026, the Department of Justice and DEA already issued a final order immediately placing FDA-approved marijuana products and state-licensed medical cannabis into Schedule III, effective April 28. The June hearing specifically addresses the remaining category—broader or adult-use cannabis—through formal evidence and testimony, with the DEA acting as proponent of the Schedule III change. Market probabilities for 2026 resolution dates reflect uncertainty over the timeline for any final DEA order or potential further procedural steps after the hearing record closes. Historical precedent shows administrative rescheduling processes can extend beyond initial hearing deadlines due to review, objections, or implementation requirements. No major new developments have been reported since the hearing window.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于$796,424 交易量
2026-03-31
9月30日
21%
12月31日
27%
$796,424 交易量
9月30日
$0 交易量
21%
12月31日
$186,853 交易量
27%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**The primary driver of trader sentiment for broader marijuana rescheduling remains the expedited DEA administrative hearing that began June 29, 2026, and was scheduled to conclude no later than July 15.** This proceeding follows President Trump's December 2025 executive order directing swift completion of the rulemaking to move cannabis from Schedule I to Schedule III under the Controlled Substances Act, building on the 2024 notice of proposed rulemaking.
In April 2026, the Department of Justice and DEA already issued a final order immediately placing FDA-approved marijuana products and state-licensed medical cannabis into Schedule III, effective April 28. The June hearing specifically addresses the remaining category—broader or adult-use cannabis—through formal evidence and testimony, with the DEA acting as proponent of the Schedule III change.
Market probabilities for 2026 resolution dates reflect uncertainty over the timeline for any final DEA order or potential further procedural steps after the hearing record closes. Historical precedent shows administrative rescheduling processes can extend beyond initial hearing deadlines due to review, objections, or implementation requirements. No major new developments have been reported since the hearing window.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
市场开放时间： Feb 7, 2026, 5:04 PM ET
交易量
$796,424结束日期
2026-03-31市场开放时间
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**The primary driver of trader sentiment for broader marijuana rescheduling remains the expedited DEA administrative hearing that began June 29, 2026, and was scheduled to conclude no later than July 15.** This proceeding follows President Trump's December 2025 executive order directing swift completion of the rulemaking to move cannabis from Schedule I to Schedule III under the Controlled Substances Act, building on the 2024 notice of proposed rulemaking.
In April 2026, the Department of Justice and DEA already issued a final order immediately placing FDA-approved marijuana products and state-licensed medical cannabis into Schedule III, effective April 28. The June hearing specifically addresses the remaining category—broader or adult-use cannabis—through formal evidence and testimony, with the DEA acting as proponent of the Schedule III change.
Market probabilities for 2026 resolution dates reflect uncertainty over the timeline for any final DEA order or potential further procedural steps after the hearing record closes. Historical precedent shows administrative rescheduling processes can extend beyond initial hearing deadlines due to review, objections, or implementation requirements. No major new developments have been reported since the hearing window.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
交易量
$796,424结束日期
2026-03-31市场开放时间
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...**The primary driver of trader sentiment for broader marijuana rescheduling remains the expedited DEA administrative hearing that began June 29, 2026, and was scheduled to conclude no later than July 15.** This proceeding follows President Trump's December 2025 executive order directing swift completion of the rulemaking to move cannabis from Schedule I to Schedule III under the Controlled Substances Act, building on the 2024 notice of proposed rulemaking. In April 2026, the Department of Justice and DEA already issued a final order immediately placing FDA-approved marijuana products and state-licensed medical cannabis into Schedule III, effective April 28. The June hearing specifically addresses the remaining category—broader or adult-use cannabis—through formal evidence and testimony, with the DEA acting as proponent of the Schedule III change. Market probabilities for 2026 resolution dates reflect uncertainty over the timeline for any final DEA order or potential further procedural steps after the hearing record closes. Historical precedent shows administrative rescheduling processes can extend beyond initial hearing deadlines due to review, objections, or implementation requirements. No major new developments have been reported since the hearing window.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于
警惕外部链接哦。
警惕外部链接哦。
常见问题